DX Deals

Siemens, California Health Network and Biopharm Research Company Partner for Enhanced Liver Fibrosis Testing

Although COVID-19 remains the driving force, non-pandemic-related strategic deal making continues. Among the most impactful deals announced in December is the partnership among Renown Institute for … [Read more...]

DX Earnings Report

Q3 Creates the Perfect Storm of Sustained COVID-19 Tailwinds and Diminishing Headwinds

July through September 2020 was a remarkable quarter for most diagnostics firms. In fact, it was the closest thing to a perfect storm for earnings. Pandemic tailwinds drove massive revenues for firms … [Read more...]

Diagnostics Deals

JetBlue Partners with Vault Health to Offer Travelers At-Home COVID-19 Testing

COVID-19 has greatly complicated air travel from country to country and even state to state. While entrance rules vary from place to place, a number of jurisdictions are allowing travelers to avoid … [Read more...]

Market Trends

COVID-19 Fuels Massive & Sustainable Growth in Molecular Diagnostics

While it may be decimating demand for most lab tests, COVID-19 is driving incredible growth in molecular testing. The global market for molecular diagnostics will top $13 billion in 2020, about $5 … [Read more...]

Diagnostic Deals

Labs, Universities and Even Computer Companies Target Point-of-Care COVID-19 Test Development

The imperative to create and provide tests capable of detecting the SARS-CoV-2 virus that causes COVID-19 coronavirus continues to fuel strategic deal making. SARS-CoV-2 point-of-care tests was the … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration

Not surprisingly, teaming up for development and commercialization of coronavirus (COVID-19) detection and vaccination products was a major theme of strategic alliance making during the period. … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: Lab Corp & Quest to Continue Targeting Small and Independent Labs for Acquisition

PAMA price cuts were supposed to drive consolidation in the lab market. The expectation was that price pressures would make it impossible for smaller labs to remain independent, rendering them juicy … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play

As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance

Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close … [Read more...]

Labs In Court

A roundup of recent cases and enforcement actions involving the diagnostics industry   Lab’s ‘False Positive’ Drug Test Report ≠ Defamation of Employee  Case: An Arkansas nurse got fired … [Read more...]


(-00000g2)